Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma (Review)

Jeng,Kuo‑Shyang; Jeng,Chi‑Juei; Jeng,Wen‑Juei; Chang,Chiung‑Fang; Sheen,I‑Shyan

doi:10.3892/ol.2017.6396

Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma (Review)

Authors:
- Kuo‑Shyang Jeng
- Chi‑Juei Jeng
- Wen‑Juei Jeng
- Chiung‑Fang Chang
- I‑Shyan Sheen
View Affiliations

Affiliations: Department of Surgery, Far Eastern Memorial Hospital, New Taipei 220, Taiwan, R.O.C., Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei 10048, Taiwan, R.O.C., Department of Hepato‑Gastroenterology, Chang Gung Memorial Hospital Lin Kau Medical Center, Chang Gung University, Taoyuan 33, Taiwan, R.O.C.
Published online on: June 16, 2017 https://doi.org/10.3892/ol.2017.6396
Pages: 1905-1910

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The efficacy of the current non‑surgical treatments for advanced hepatocellular carcinoma (HCC) remains limited and novel treatments are required to improve patient outcomes. The majority of HCCs develop from chronically damaged tissue that contains a high degree of inflammation and fibrosis, which promotes tumor progression and resistance to therapy. Understanding the interaction between stromal components and cancer cells (and the signaling pathways involved in this interaction) could aid the identification of novel therapeutic targets. Numerous studies have demonstrated a marked association between high C‑X‑C chemokine receptor 4 (CXCR4) expression and the invasiveness, progression and metastasis of HCC. The present review will investigate the different roles of CXCR4 in the progression of HCC and discuss possible future treatments. Through the C‑X‑C chemokine ligand 12 (CXCL12)/CXCR4 signaling pathway, ephrin A1 activation enhances the migration of endothelial progenitor cells to HCC to enable the neovascularization of tumors. There is an association between nuclear CXCR4 expression and the lymph node metastasis of HCC to distant areas. CXCR4 enhances cell migration in vitro and cell homing in vivo. CXCR4 levels are concentrated at the border of a tumor and in perivascular areas, inducing invasive behavior. The binding of CXCL12 to CXCR4 activates intracellular signaling pathways and induces crosstalk with transforming growth factor‑β signaling, which enhances the migration of cancer cells. The CXCL12/CXCR4 axis also activates expression of matrix metalloproteinase 10, which further stimulates migration. CXCR4 is likely to crosstalk with the sonic hedgehog signaling pathway, contributing to tumor invasiveness and supporting the cancer stem‑cell population; as a result, CXCR4 can be regarded as a cancer stem‑cell marker. CXCR4 influences interstitial fluid flow‑induced invasion. CXCR4 expression and HCC cell migration are promoted by α‑fetoprotein, which activates AKT/mechanistic target of rapamycin signaling. CXCR4 also has the potential to affect sorafenib treatment for HCC. Targeting the CXCL12/CXCR4 signaling pathway may, therefore, be a promising strategy in HCC treatment.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Waller LP, Deshpande V and Pyrsopoulos N: Hepatocellular carcinoma: A comprehensive review. World J Hepatol. 7:2648–2663. 2015. View Article : Google Scholar : PubMed/NCBI
3	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hernandez-Gea V, Toffanin S, Friedman SL and Llovet JM: Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 144:512–527. 2013. View Article : Google Scholar : PubMed/NCBI
5	Gorbachev AV and Fairchild RL: Regulation of chemokine expression in the tumor microenvironment. Crit Rev Immunol. 34:103–120. 2014. View Article : Google Scholar : PubMed/NCBI
6	Horuk R: Chemokine receptors. Cytokine Growth Factor Rev. 12:313–335. 2001. View Article : Google Scholar : PubMed/NCBI
7	Singh S, Sadanandam A and Singh RK: Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev. 26:453–467. 2007. View Article : Google Scholar : PubMed/NCBI
8	Singh R, Lillard JW Jr and Singh S: Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed). 3:1569–1582. 2011. View Article : Google Scholar : PubMed/NCBI
9	Stone MJ, Hayward JA, Huang C, E Huma Z and Sanchez J: Mechanisms of Regulation of the Chemokine-Receptor Network. Int J Mol Sci. 18(pii): E3422017. View Article : Google Scholar : PubMed/NCBI
10	Guo JC, Li J, Zhou L, Yang JY, Zhang ZG, Liang ZY, Zhou WX, You L, Zhang TP and Zhao YP: CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer. Oncotarget. 7:62006–62018. 2016.PubMed/NCBI
11	Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J and Ratajczak MZ: Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 23:879–894. 2005. View Article : Google Scholar : PubMed/NCBI
12	Chatterjee S, Azad B Behnam and Nimmagadda S: The intricate role of CXCR4 in cancer. Adv Cancer Res. 124:31–82. 2014. View Article : Google Scholar : PubMed/NCBI
13	Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
14	Shibuta K, Mori M, Shimoda K, Inoue H, Mitra P and Barnard GF: Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation. Jpn J Cancer Res. 93:789–797. 2002. View Article : Google Scholar : PubMed/NCBI
15	Liu H, Pan Z, Li A, Fu S, Lei Y, Sun H, Wu M and Zhou W: Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol. 5:373–378. 2008. View Article : Google Scholar : PubMed/NCBI
16	Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang PY, Liang Y, Tan YS and He J: Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer. 9:1762009. View Article : Google Scholar : PubMed/NCBI
17	Zhao S, Wang J and Qin C: Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. J Exp Clin Cancer Res. 33:1032014. View Article : Google Scholar : PubMed/NCBI
18	Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM and Raymond E: Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res. 6:340–352. 2014.PubMed/NCBI
19	Hu F, Miao L, Zhao Y, Xiao YY and Xu Q: A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma. Drug Des Devel Ther. 9:3625–3633. 2015. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Yu H, Shan Y, Tao C, Wu F, Yu Z, Guo P, Huang J, Li J, Zhu Q, et al: EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway. J Exp Clin Cancer Res. 35:652016. View Article : Google Scholar : PubMed/NCBI
21	Xi HQ, Wu XS, Wei B and Chen L: Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med. 16:2894–2909. 2012. View Article : Google Scholar : PubMed/NCBI
22	Schimanski CC, Bahre R, Gockel I, Müller A, Frerichs K, Hörner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T, et al: Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer. 95:210–217. 2006. View Article : Google Scholar : PubMed/NCBI
23	Xiang ZL, Zeng ZC, Tang ZY, Fan J, Sun HC, Wu WZ and Tan YS: Nuclear accumulation of CXCR4 and overexpressions of VEGF-C and CK19 are associated with a higher risk of lymph node metastasis in hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi. 32:344–349. 2010.(In Chinese). PubMed/NCBI
24	Kim SW, Kim HY, Song IC, Jin SA, Lee HJ, Yun HJ, Kim S and Jo DY: Cytoplasmic trapping of CXCR4 in hepatocellular carcinoma cell lines. Cancer Res Treat. 40:53–61. 2008. View Article : Google Scholar : PubMed/NCBI
25	Ishii T, Nishihara M, Ma F, Ebihara Y, Tsuji K, Asano S, Nakahata T and Maekawa T: Expression of stromal cell-derived factor-1/pre-B cell growth-stimulating factor receptor, CXC chemokine receptor 4, on CD34+ human bone marrow cells is a phenotypic alteration for committed lymphoid progenitors. J Immunol. 163:3612–3620. 1999.PubMed/NCBI
26	Kollet O, Shivtiel S, Chen YQ, Suriawinata J, Thung SN, Dabeva MD, Kahn J, Spiegel A, Dar A, Samira S, et al: HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest. 112:160–169. 2003. View Article : Google Scholar : PubMed/NCBI
27	Dar A, Kollet O and Lapidot T: Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol. 34:967–975. 2006. View Article : Google Scholar : PubMed/NCBI
28	Bertran E, Crosas-Molist E, Sancho P, Caja L, Lopez-Luque J, Navarro E, Egea G, Lastra R, Serrano T, Ramos E and Fabregat I: Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology. 58:2032–2044. 2013. View Article : Google Scholar : PubMed/NCBI
29	Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Vlahakis N and Paya CV: G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol. 169:5546–5554. 2002. View Article : Google Scholar : PubMed/NCBI
30	Bertran E, Caja L, Navarro E, Sancho P, Mainez J, Murillo MM, Vinyals A, Fabra A and Fabregat I: Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. Cell Signal. 21:1595–1606. 2009. View Article : Google Scholar : PubMed/NCBI
31	García-Irigoyen O, Latasa MU, Carotti S, Uriarte I, Elizalde M, Urtasun R, Vespasiani-Gentilucci U, Morini S, Benito P, Ladero JM, et al: Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis. Hepatology. 62:166–178. 2015. View Article : Google Scholar : PubMed/NCBI
32	Jeng KS, Sheen IS, Jeng WJ, Yu MC, Tsai HH, Chang FY and Su JC: Blockade of the sonic hedgehog pathway effectively inhibits the growth of hepatoma in mice: An in vivo study. Oncol Lett. 4:1158–1162. 2012.PubMed/NCBI
33	Jeng KS, Sheen IS, Jeng WJ, Yu MC, Hsiau HI, Chang FY and Tsai HH: Activation of the sonic hedgehog signaling pathway occurs in the CD133 positive cells of mouse liver cancer Hepa 1–6 cells. Onco Targets Ther. 6:1047–1055. 2013. View Article : Google Scholar : PubMed/NCBI
34	Jeng KS, Sheen IS, Jeng WJ, Lin CC, Lin CK, Su JC, Yu MC and Fang HY: High expression of patched homolog-1 messenger RNA and glioma-associated oncogene-1 messenger RNA of sonic hedgehog signaling pathway indicates a risk of postresection recurrence of hepatocellular carcinoma. Ann Surg Oncol. 20:464–473. 2013. View Article : Google Scholar : PubMed/NCBI
35	Jeng KS, Sheen IS, Jeng WJ, Yu MC, Hsiau HI and Chang FY: High expression of Sonic Hedgehog signaling pathway genes indicates a risk of recurrence of breast carcinoma. Onco Targets Ther. 7:79–86. 2013. View Article : Google Scholar : PubMed/NCBI
36	Singh AP, Arora S, Bhardwaj A, Srivastava SK, Kadakia MP, Wang B, Grizzle WE, Owen LB and Singh S: CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: Implications for bidirectional tumor-stromal interactions. J Biol Chem. 287:39115–39124. 2012. View Article : Google Scholar : PubMed/NCBI
37	Sengupta R, Dubuc A, Ward S, Yang L, Northcott P, Woerner BM, Kroll K, Luo J, Taylor MD, Wechsler-Reya RJ and Rubin JB: CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res. 72:122–132. 2012. View Article : Google Scholar : PubMed/NCBI
38	Tomuleasa C, Soritau O, Rus-Ciuca D, Pop T, Todea D, Mosteanu O, Pintea B, Foris V, Susman S, Kacsó G and Irimie A: Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis. 19:61–67. 2010.PubMed/NCBI
39	Zhu L, Zhang W, Wang J and Liu R: Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma. Tumour Biol. 36:5353–5360. 2015. View Article : Google Scholar : PubMed/NCBI
40	Sukowati CH, Anfuso B, Torre G, Francalanci P, Crocè LS and Tiribelli C: The expression of CD90/Thy-1 in hepatocellular carcinoma: An in vivo and in vitro study. PLoS One. 8:e768302013. View Article : Google Scholar : PubMed/NCBI
41	Yu C, Wang Z, Xu X, Xiang W and Huang X: Circulating hepatocellular carcinoma cells are characterized by CXCR4 and MMP26. Cell Physiol Biochem. 36:2393–2402. 2015. View Article : Google Scholar : PubMed/NCBI
42	Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 13:153–166. 2008. View Article : Google Scholar : PubMed/NCBI
43	Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, Li ML, Tam KH, Lam CT, Poon RT and Fan ST: Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 47:919–928. 2008. View Article : Google Scholar : PubMed/NCBI
44	Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, Sung PS, Song MJ, Lee BC, Hwang D and Yoon SK: CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 315:129–137. 2012. View Article : Google Scholar : PubMed/NCBI
45	Shah AD, Bouchard MJ and Shieh AC: Interstitial fluid flow increases hepatocellular carcinoma cell invasion through CXCR4/CXCL12 and MEK/ERK Signaling. PLoS One. 10:e01423372015. View Article : Google Scholar : PubMed/NCBI
46	Honma N, Genda T, Matsuda Y, Yamagiwa S, Takamura M, Ichida T and Aoyagi Y: MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. Lab Invest. 86:687–696. 2006. View Article : Google Scholar : PubMed/NCBI
47	Zhu M, Guo J, Xia H, Li W, Lu Y, Dong X, Chen Y, Xie X, Fu S and Li M: Alpha-fetoprotein activates AKT/mTOR signaling to promote CXCR4 expression and migration of hepatoma cells. Oncoscience. 2:59–70. 2015. View Article : Google Scholar : PubMed/NCBI
48	Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, et al: Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 59:1435–1447. 2014. View Article : Google Scholar : PubMed/NCBI
49	Gao DY, Lin TsT, Sung YC, Liu YC, Chiang WH, Chang CC, Liu JY and Chen Y: CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 67:194–203. 2015. View Article : Google Scholar : PubMed/NCBI